Groundbreaking First Human Trial For The 'Mother Of All Cannabinoids' Begins

Study found that CBG significantly reduced anxiety and stress levels in participants, with additional benefits observed in verbal memory performance.

Cannabis has been an herb of medicinal interest for quite a long time. Researchers are just at the threshold of finding new applications for the plant. Cannabigerol, one of the lesser-known compounds in cannabis, is taking centre stage and may end up being the next CBD rival in the near future.

In a breakthrough human clinical trial, researchers tested how CBG affects anxiety and stress. The study involved 34 healthy participants who reported feeling significantly less anxious and stressed an hour after taking a tincture containing CBG compared to a placebo. An unexpected finding was that participants also performed slightly better in verbal memory tests after being dosed with CBG. Previous studies have shown that THC-or tetrahydrocannabinol, the psychoactive compound in cannabis-is known to impair verbal memory.

Deservedly, CBG has come to be known as the "mother of all cannabinoids" because it easily and quickly metabolises into both CBD and THC. Unlike THC, however, CBG does not get one high.